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Abstract 
 
Background: As a drug target and an antigenic agent, HIV-1 protease (HIV-1 PR) is 
at the center of attention for designing anti-AIDS inhibitors and diagnostic tests. In 
previous studies, the production of the recombinant protease has been faced with 
several difficulties; therefore, the aims of this study were the easy production, purifica-
tion of the soluble form of protease in E. coli and investigation of its immunoreactivity. 
 
Methods: Protease coding region was isolated from the serum of an infected individu-
al, amplified by RT-PCR and cloned into PTZ57R using TA-cloning. Protease coding 
frame was isolated by PCR and cloned in pET102/D. TOPO expression vector and 
cloned protease was expressed in Escherichia coli (E. coli) BL21. Produced recombinant 
protein was purified by affinity Ni-NTA column and protein concentration was 
checked by BCA protein assay kit. Subsequently, immunoreactivity of recombinant 
protease (rPR) was assayed by Western blotting and ELISA.  
 
Results: Cloning of the HIV protease by TOPO cloning system in pET102/D.TOPO was 
confirmed with PCR and sequencing. The concentration range of purified recombi-
nant protein was 85 to 100 g/ml. Immunogenicity of rPR was confirmed by Western 
blotting and ELISA. 
 
Conclusion: Soluble production of recombinant HIV-1 protease (HIV-1 rPR) was per-
formed successfully. This recombinant protein disclosed 86% specificity and 90% sensi-
tivity in immunoassay tests. 
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Introduction 
Two pathogenic types of Human Immunodeficiency 
Virus (HIV) are known as HIV-1 and HIV-2. HIV-1 is 
the predominant virus in most parts of the world 1. At 
present, HIV-1 phylogenetic classifications are based 
on genome sequence analysis that leads to identifying 
of inter-subtype recombinant forms named Circulatory 
Recombinant Forms (CRFs) 2. CRF35_AD is one of 
the highly prevalent forms of HIV-1 in Iran and Af-
ghanistan that should be more investigated 3. Following 
its recognition in 1981, the HIV/AIDS epidemic has 
evolved to become the greatest challenge in global 
health, with some 34 million persons living with HIV 
worldwide 4. HIV diagnosis is very critical for effective  
 
 
 
 
 
preventive strategies and designing a plan for positive 
cases. HIV/AIDS testing is based on immunoblotting 
assays (ELISA, Western blotting) and viral nucleic 
acid test. Also, antiviral therapy in AIDS is based on 
inhibitors that target the vital component of the virus 5.   
HIV-1 is a RNA virus of retrovirus family whose 
genes are initially transcribed as GAG, POL and ENV 
poly-protein precursor that needs to be cleaved for 
completing viral life cycle 6. HIV-1 protease (HIV-1 
PR) derived from pol polyprotein is an aspartic prote-
ase which acts in homo-dimer form 7-9. It processes the 
viral gag, gag-pol and env to the mature structural and 
enzymatically active proteins and it is essential for the 
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viral life cycle, so that point mutations inactivating this 
enzyme have given rise to the production of noninfec-
tious progeny virus 10. Accordingly, the HIV-1 protease 
is one of the main targets for anti-HIV drug therapy 11. 
Although standard treatment with current protease in-
hibitors is somehow effective, these inhibitors have 
some limitation such as drug-resistance and non-
response 12. Therefore, easy production and purifica-
tion of large quantities of this enzyme are pre-re-
quisites for the development of assays which allow the 
identification of potent and selective inhibitors.  
On the other hand, previous studies have shown that 
HIV-1 PR can trigger host immune system. This en-
zyme has several conserved epitopes that play a role in 
epitope selection and immunodominance 13. Enzyme-
linked Immunoassay (EIA) of a bacterially expressed 
protease indicated that most individuals developed an 
antibody response to protease. So, protease seems to be 
quite antigenic 14. Given the importance of AIDS diag-
nosis for preventing infection transmission and man-
agement of infected individuals, heterogeneous produc-
tion of protease can promote the specificity and sensi-
tivity of immunoblotting and ELISA diagnostic assays. 
Because of cytotoxicity and hydrophobicity (low 
solubility) of protease, it is difficult to obtain large 
quantities, so that in most cases, the expression level 
has been low and it can only be detected by immuno-
blotting 15. Therefore, the main purposes of this study 
were to construct a high and reproducible expression 
system for production of recombinant HIV-1 protease 
(HIV-1 rPR), establish a convenient (simple and fast) 
purification procedure and finally test the immunogen-
icity feature of HIV-1rPR using immunoblotting and 
Enzyme-Linked Immunosorbent Assay (ELISA).  
 
Materials and Methods 
 
Sample preparation 
Serum samples of HIV-1 positive patients were pro-
vided by virology lab of the Iranian Blood Transfusion 
Organization (IBTO). All samples had been confirmed 
to be either HIV positive or negative by Western blot-
ting and real-time PCR. 
 
Viral RNA isolation and RT-PCR 
Viral RNA was isolated from HIV positive serum 
samples using the Viral RNA extraction Mini Kit (Qia-
gen, USA) according to the manufacturer’s instruc-
tions. Synthesis of cDNA was done under following 
conditions: 5 μg of isolated viral RNA was added to 
RT reaction mixture containing 20 units of PrimeScript 
™RTase (200 U/µl), 100 pmol of random hexamer,  
4 μl of 5 x RT buffer, 20 units of Thermo Scientific 
RiboLock RNase inhibitor, and 10 mM of dNTPs mix 
(all from Fermentas, Lithuania) adjusted to the final 
volume of 20 μl with d.H2O. The mixture was then 
incubated for 10 min at 25°C followed by 60 min at 
37°C. Termination of the reaction was done by heating 
at 75°C for 8 min.  
Nested PCR was carried out using cDNA samples 
with external and internal primer pairs listed in table 1. 
RT-PCR reaction was performed for achievement of 
504 bp A-tailed PCR product using Taq DNA poly-
merase (Fermentas, Lithuania) according to following 
thermal cycle program: denaturation at 94°C for 5 min, 
34 cycles of 94°C for 1 min, 58°C for 30 s, and 72°C 
for 60 s. A final extension cycle was run at 72°C for 10 
min. The PCR products were purified using PCR 
Cleanup Kit (Roche, Germany). Then, purified PCR 
products were cloned into PTZ57R (T) vector using 
InsTAclone PCR Cloning Kit (Fermentas, Lithuania). 
All procedures were accomplished according to the 
instruction manuals provided by kit manufacturers. 
Confirmation of insertion of the PR coding sequence 
was carried out by sequencing of PTZ57R-PR and col-
ony-PCR (FAZA Biotech Co, Tehran, Iran). 
 
Cloning and expression of PR coding region in pET102D/ 
TOPO expression vector 
The primers set of Fprot and Rprot (Table 1) were 
designed for amplification of PR coding sequence from 
PTZ57R-PR. CACC base at the start of forward primer 
is for direct insertion of blunt end PCR product into 
TOPO cloning vector. DNA encoding PR was ampli-
fied using pfu DNA polymerase (Stratagen, USA) in a 
gradient master cycler (Eppendorf, Hamburg, Germa-
ny) as follows: initial denaturation at 96°C for 4 min, 
30 cycles consisted of denaturation at 94°C for 45 s, 
annealing at 58°C for 30 s and extension at 72°C for  
40 s. A final extension cycle was performed at 72°C 
for 5 min. Amplified PR coding region was purified 
and inserted into the pET102D/TOPO expression vec-
tor (Invitrogen, USA) according to the manufacture 
instruction, and transformed into BL21 (DE3) Esche-
richia coli (E. coli) strain. Obtained transformed E. coli 
was cultured on LB agar medium including 100 ng/μl 
ampicillin, 40 µl of X-Gal stock solution (20 mg/ml) 
Table 1. Nucleotide sequence of the primers used for amplification of region containing protease gene 
 
Primer Target Sequence on HXB2 Reference Sequence (GenBank: AF033819.3) Primer sequence (5’ to 3’) 
External ProtF 1627-1654 TAATTTTTTAGGGAAGATCTGGCCTTCC 
External ProtR 2280-2248 GCAAATACTGGAGTATTGTATGGATTTTCAGG 
Internal ProtF 1681-1709 TCAGAGCAGACCAGAGCCAACAGCCCCA 
Internal ProtR 2196-2166 AATGCTTTTATTTTTTCTTCTGTCAATGGC 
Primers used for TOPO-cloning   
 Fprot 
5'CACCCCTCAAATCACTCTTTGGCAA3' 
5'AAAATTTAAAGTACAACCAATTTGGGTCA3' 
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and 40 µl of IPTG 100 mM. White colonies are consid-
ered as recombinant bacteria and both colony-PCR and 
sequencing were accomplished for analysis of recom-
binant clones.  
True recombinant E. coli BL21 (DE3) was then cul-
tured overnight at 37°C in LB medium containing 100 
ng/μl ampicillin. In the following day, 500 μl of over-
night culture was added to 250 ml of fresh LB medium 
in a shaker incubator (150 rpm) at 37°C for 5 hr until 
the logarithmic phase (OD600=0.5-0.6). E. coli BL21 
(DE3) cells were then induced by IPTG at a final con-
centration of 0.1 M for 4 hr at 37°C. After 4 hr, E. coli 
pellet was harvested using centrifugation at 3500 rpm 
(Eppendorf 5804) for 12 min and used for subsequent 
analysis including expression confirmation, purifica-
tion and immunoblotting assays. 
 
Expression analysis and purification of recombinant protein 
Achieved induced E. coli pellet was sonicated by ul-
trasonic system UP100H (Hielscher Inc, USA). For 
this purpose, cell pellet was resuspended in chilled 
lysis buffer (50 mM Tris-HCl pH=7.5, 100 mM NaCl, 5 
mM DTT, 1 mM PMSF) and cooled on ice for 10 min. 
Then, cell suspension was sonicated with 10 short 
bursts of 10 s followed by interval of 30 s for cooling. 
Finally, cell debris was removed by ultracentrifugation 
at 4°C for 15 min at 14000 rpm. For confirmation of 
rPR expression, the supernatant was run on 12% poly-
acrylamide gel and analyzed by SDS-PAGE and West-
ern blotting. Purification of rPR was done using Ni2+-
NTA resin (Invitrogen, USA) according to the manu-
facturer’s guide. In this stage, native purification meth-
od was used. The purity of the purified protein was 
assessed using electrophoresis on the 12% polyacryla-
mide gel and subsequent Coomassie blue staining.  
Purified protein concentration was measured by Micro 
BCA protein assay kit (PIERCE, USA). 
 
Immunoblotting and ELISA 
Following the acrylamide gel electrophoresis, the 
protein bands were transferred to the nitrocellulose 
membrane. Blocking of the membrane was developed 
with 5% of skim milk in TBST buffer (Tris-Buffered 
Saline containing 0.1% v/v Tween 20) for 1.5 hr and 
incubated overnight in a shaker at 4°C. On the follow-
ing day, membrane was incubated with human serum 
of patient infected with HIV-1 diluted 1:12000 in 3% 
skim milk and TBS buffer for 3 hr on a shaker at 37°C. 
The membrane was washed 3 times with TBST buffer 
and incubated with mouse anti human-HRP antibody 
diluted 1:90,000 in 3% skim milk in TBS buffer for  
3 hr at Room Temperature (RT) on a shaker. Again, 
membrane was washed 3 times with TBST and 1 time 
with PBS buffer. Thermo Scientific™ Pierce ECL 
Western Blotting Substrate (Thermo Fisher Scientific, 
Wyman Street, Waltham, USA) was added to mem-
brane and blotting results were visualized using a light-
sensitive film. In parallel, another Western blot analy-
sis was performed using anti-His tag monoclonal anti-
body (Invitrogen, Frankfurt, Germany) diluted 1:2000 
in 3% skim milk in TBS buffer. This antibody specif-
ically binds to poly-histidine tag of the recombinant 
protein and confirms the expression of the recombinant 
protease.  
In this study, ELISA was performed to test specif-
icity and sensitivity property of rPR. To do this, Maxi-
Sorp 96-well plates ((Nunc Technologies, Roskilde) 
were used in which hydrophilic HP-thioredoxin rPR 
coats its surface with high efficacy.  80 μg.μL-1 purified 
rPR suspended in 0.1 M PBS (pH=7.5) was used for 
coating and incubated overnight at 4°C. On the follow-
ing day, 96 wells of microtiter plate were washed 3 
times with Phosphate Buffer Saline (PBS) and blocked 
with 5% BSA in PBS for 1.5 hr at RT. Plate was 
washed 5 times with PBST buffer (containing PBS and 
0.2 Tween 20). HIV- infected and healthy control sera 
diluted 1:300 in PBS containing 0.1% (v/v) Tween-20 
and 0.01% (w/v) BSA were applied to each well and 
incubated at 37°C for 40 min. All wells were con-
sequently washed 5 times with PBST, 1:2000 dilution 
of secondary mouse antihuman-ALP conjugated anti-
body in PBS added to each well and the plate was in-
cubated for 1 hr at RT. Again, each well was washed 3 
times to remove the unbinding antibodies. Finally, the 
plate was incubated with 100 µl of PNPP for 30 min 
and applied to ELISA reader (Biochrome, Cambridge, 
UK) at OD450. Specificity and sensitivity values of rPR 
were evaluated by 50 positive and 50 negative serum 
samples. ELISA results were analyzed using receiver 
operating characteristic (ROC) analysis by SPSS soft-
ware, version 16.0 (SPSS Inc, Chicago, IL) and cut-off 
(CO) values for the test were set according to Youden's 
index. According to this index, the maximum CO value 
set to 0.78 was equal to the point where Y=sensitivity+ 
(specificity-1). 
 
Results 
 
RT-PCR and amplification of protease gene from PTZ57R-
PR  
RT-nested PCR product of the region containing 
protease gene was visualized on 1% agarose gel (Fig-
ure 1A). For this purpose, a fragment with 504 bp was 
successfully amplified and recombinant colonies har-
boring PTZ57R-PR were confirmed by colony PCR 
and sequencing. Then, the blunt end DNA encoding PR 
sequence was PCR amplified from PTZ57R-PR and 
visualized on 1.5% agarose gel (Figure 1B). Sequenc-
ing result of cloned PR sequence with specific primers 
clarified coding sequence of CRF35_AD subtype of 
HIV-1 virus which is highly prevalent in Iran and Af-
ghanistan [identities=298/299 (99%) and gaps=0/299 
(0%)], except a substitution at position 262 (A>G) in 
our query. Since the genome of retroviruses is ampli-
fied by an error prone reverse transcriptase, the ge-
nome of these viruses is susceptible to changing during 
life cycle of virus. Therefore, this phenomenon is likely 
reasonable that why our sequencing result showed 99% 
17
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homology, and not 100%. ORF analysis showed that 
PR coding region has been inserted in-frame so that it 
will be expressed next to N-terminus HP-thioredoxin 
fusion and C-terminus V5 epitope and (6X) His-tag. 
 
Expression of protease recombinant protein in E. coli BL21 
In TOPO-Cloning system, recombinant proteins are 
expressed in fusion with (6X) His-tag and HP-thio-
redoxin that increase the molecular weight of the prod-
uct about 17 kDa. Since protease has a molecular 
weight of 11 kDa, it must be seen as a distinct 28-kDa 
band in SDS-PAGE and Western blot. Study of protein 
expression by SDS-PAGE and Western blot with anti-
His Tag antibody showed that the protein expression of 
cloned rPR was performed well after induction with 
IPTG (Figures 2A and 2B). In SDS-PAGE analysis, a 
distinct band of approximately 28 kDa was seen after 
induction (Figure 2A), whereas there was no expres-
sion of rPR fusion protein in transformed BL21 (DE3) 
without IPTG induction and BL21 (DE3) without re-
combinant pET102D/TOPO expression vector (as neg-
ative control). SDS-PAGE analysis and subsequent Co-
omassie blue staining of resultant supernatant obtained 
from centrifugation of sonicated cell suspension indi-
cated that recombinant protease was expressed in solu-
ble form (Figure 2).  
 
Purification of recombinant protease 
Since the recombinant protease expression was ob-
served in soluble form, native protein purification ap-
proach was used to maintain the structure and function 
of protein. Protein purification was developed using 
Ni-NTA affinity chromatography where the His-Tag 
and HP-thioredoxin are attached to nickel ion. The 
concentration of the purified recombinant protein 
measured by Micro BCA protein assay kit (PIERCE, 
USA) was 85 to 100 µg/ml in different dilutions. For 
identification and confirmation of produced rPR, 
Western blotting with anti-His Tag and SDS-PAGE 
analysis were carried out. Clear bands corresponding to 
28 kDa molecular weight were observed (Figures 2A 
and 2B). 
 
Specificity and sensitivity of recombinant protease in im-
munoblotting and ELISA assay 
Western blotting and ELISA assay were performed 
for identification and confirmation of immunoreactiv-
ity of produced rPR. Western blotting with HIV+ se-
rum was carried out and results disclosed that produced 
rPR reacted specifically with antibodies which most 
probably were raised by the immune system against 
protease antigen (Figure 3). 
ELISA assay was done for pre-confirmed 50 HIV+ 
and 50 HIV-sera. Statistical analysis was performed 
based on ROC analysis and Youden’s index. Our 
ELISA assay developed in this study could detect 45 
out of 50 positive samples and was negative for 43 out 
of 50 negative sera, therefore, sensitivity and specifici-
ty values of rPR immunoreactivity were seen to be 90 
and 86%, respectively (Table 2). 
Figure 1. A) Gel agarose visualization of PCR products amplified by 
internal primers after amplification of cDNA as template. M (DNA 
marker); 1-3 (interest fragment amplified in optimized Tm=58°C); 4 
(negative control, human genomic DNA); B) PCR amplification re-
sults of the PTZ57R-PR vector containing protease ORF (301 bp). 
Lanes 1 and 2 (DNA marker); lanes 3-6 (amplified by Taq DNA 
polymerase); lanes 7-8 (amplified by pfu DNA polymerase); lane 9 
(negative control). 
Figure 2. A) SDS-PAGE analysis of recombinant fusion thioredoxin-
PR protein on 12% polyacrylamide gel. Lane M: prestained protein 
molecular marker (Thermo Scientific Pierce Prestained Protein MW 
Marker); Lane 1: sonicated BL21 (DE3) crude cell lysate harboring 
recombinant plasmid after induction with IPTG; lanes 7 and 8: rPR 
protein purified by Ni2+-NTA resin column affinity chromatography; 
Lanes 2-6: E. coli BL21 (DE3) lysate without recombinant vector 
(negative control); B) Confirmation of the recombinant PR protein 
production by Western blot analysis with mouse anti-HIS tag anti-
body. Lane 1, purified recombinant PR; lane 2, cell lysate harboring 
recombinant plasmid after induction; lane 3, host cell without recom-
binant plasmid (negative control). 
Figure 3. Western blot analysis of the rPR protein (28 kDa) with HIV-
infected serum. Lane 1, purified recombinant PR; lane 2, cell lysate of 
E. coli harboring recombinant plasmid Pet102-PR; lane 3, host cell 
without recombinant plasmid Pet102-PR. 
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Discussion 
 
The protease enzyme was expressed as a fusion re-
combinant protein with His tag and thioredoxin in ac-
ceptable concentration of 85-100 μg/ml. In general, 
purification products in prior studies using E. coli sys-
tem have been less than 1 mg/L and in cases with the 
high expression level (20-30 mg/L), reproducibility has 
been the problem 16-18.   
In previous studies, different strategies were inves-
tigated  in order to produce large amounts of HIV-1 Pr, 
including i) autocatalytic processing of a larger precur-
sor ii) fusing to a variety of proteins, e.g., lactamase, 
Glutathione S-Transferase (GST) and maltose-binding 
protein fused to N-terminal portion of interferon, or as 
His-tagged recombinant protein iii) codon usage, A+T  
 
richness at the 5′ end of the coding region, and opti-
mizing promoter and iv)  recovering by refolding E. 
coli inclusion bodies 16,18-25. In these studies, producing 
rPR has been faced with problems such as toxicity, 
hydrophobicity, and purification. In this study, pET- 
102/D.TOPO expression system was used to overcome  
 
 
the mentioned problems. For the production of rPR 
protein, the sequence from isolate IBTO-1 and PR was 
cloned containing region in a vector PTZ57R-PR. After 
sub-cloning to Pet102/D.TOPO expression vector, PR 
coding ORF was expressed in fusion with thioredoxin  
 
under T7 promoter control in E. coli. N-terminus thio-
redoxin fusion will promote protein folding, expres-
sion, and solubility as proved by others 26-30. Further-
more, increased solubility will decrease the formation  
 
of inclusion body and will ease the purification of re-
combinant proteins. On the other hand, the position of 
the cloning site in the vector used in this study is de-
signed so that 6x histidine tag is added to the beginning 
and end of the protein. The existence of such histidine 
tags makes produced recombinant protein to be puri-
fied easily by the nickel affinity chromatography 31.  
 
Single-step purification of rPR was successfully done 
using nickel affinity column. The purity of the product 
was estimated to be more than 95% by SDS-PAGE and 
subsequent Coomassie blue staining (Figure 2B). In a  
 
study, Gorjipour et al also used our cloning system for 
production of recombinant HIV-1 P24 32. According to 
their results, the amount of produced protein was 120 
μg/ml less than the amount of rPR production. The 
reason can be probably due to the highly toxic property 
of protease for the host. 
On the other hand, diagnosis of HIV-infected in-
dividuals is a primary task that allows health providers 
to screen and identify the virus carriers which help 
prevention of infection transmission and on time treat-
ment. Immunoreactivity of purified rPR was tested by 
Western blotting and ELISA. Compared with ELISA, 
Western blotting is more specific but less sensitive. In 
some studies, immunoreactivity of HIV-1 PR has 
showed the reactivity with sera of more than 50% of 
individuals infected with HIV-1 14. Bjorling et al found 
that HIV-1 protease has four different antigenic regions 
where the most prominent reactivity was resulted from 
amino acid 44-58 known as flap region 33. In another 
study, hamster monoclonal antibody showed a high 
specific reaction with HIV-1 protease demonstrating 
considerable antigenic characteristics of protease 34. 
Interestingly, in the study conducted by Hallengärd et 
al demonstrated that inactivation of protease enzyme 
activity significantly increases its in vitro expression as 
well as in vivo immunogenicity 35. Therefore, these 
findings are indicating that protease can be a good 
candidate in diagnostic and vaccine design approaches. 
One of the major goals of the current study was to 
validate the immunoreactivity of the rPR with HIV-1 
infected sera. In the present study, Western blotting 
and ELISA assays were carried out. Our Western re-
sults revealed that produced rPR reacts with HIV-1 
infected sera specifically (Figure 3). Also, ELISA data 
disclosed that protease is approximately a strong anti-
gen where testing of 50 HIV-1 positive and 50 HIV-1 
negative serum samples disclosed that the recombinant 
protein produced in this study has the diagnostic values 
of 90% sensitivity and 86% specificity (Table 2). So, 
our findings confirm the results of some previous 
studies.  
In the present study, rPR was produced in fusion 
with HP-thioredoxin. In addition to enabling high level 
expression of recombinant fusion proteins, HP-thiore-
doxin has indicated the increases of coating efficiency 
by adsorption to the MaxiSorp MicroWell surfaces and 
consequently the increases in the efficiency of ELISA 
32. Nonetheless, the role of fused protein tag in specif-
icity of the final product isn’t clear and can be con-
sidered in next studies.  
 
Conclusion 
 
Taking together, HIV-1 protease is one of the key 
enzymes that plays an important role in viral matura-
tion so that it has been an AIDS inhibitor target for a 
long time 6. Nonetheless, little attention has been paid 
to studying the antigenic properties of protease in diag-
nostic and vaccine design programs. Recombinant pro-
tease in high quantity and soluble form at lab-scale was 
produced. Highly expressed rPR in this experiment can 
provide a cheap and highly qualified candidate for use 
in the diagnostic tests for the serodiagnosis of HIV-1 
infection. Accompanied with other HIV-1 antigens, 
detection of antibodies using this recombinant antigen 
Table 2. ELISA results of 50 serum samples of the confirmed infected 
individuals with HIV and 50 negative serum samples as the control 
 
Statistic Value 95% CI 
Sensitivity 90% 78.19%-96.67% 
Specificity 86% 73.26%-94.18% 
Positive Predictive Value (PPV) 86.54% 74.21%-94.41% 
Negative Predictive Value (NPV) 89.58% 77.34%-96.53% 
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can provide a platform for screening and detection of 
HIV-1 infection in screening programs. Although the 
potency of this antigen was not studied for the induc-
tion of immune response, it is expected to be a poten-
tial target in further studies including production of 
monoclonal antibody and vaccine design.    
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